Authors' objectives: Ovarian cancer is the fifth most common cancer for women in the UK. Symptoms of ovarian cancer are often vague early on and many women are not diagnosed until after the cancer has grown and spread to other parts of the body. Less than half of women with ovarian cancer survive five years from diagnosis with many becoming resistant to current treatments. Ovarian, fallopian tube and primary peritoneal cancer all begin in the same part of the ovary or fallopian tube. Binimetinib is a new drug for the treatment of ovarian, fallopian tube or primary peritoneal cancer. It is taken as a tablet. If binimetinib is licensed for use in the UK, it could be a new treatment option for patients with ovarian, fallopian tube or primary peritoneal cancer. This may improve survival when current treatments have stopped working.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/binimetinib-for-recurrent-or-persistent-ovarian-fallopian-tube-or-primary-peritoneal-cancer-second-and-subsequent-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)